FDA’s Overcaution Carries Deadly Consequences

Featuring Mark Flatten and Caleb O. Brown

When the FDA sets out to evaluate a potential new drug, the agency's overcaution makes the exercise more expensive and potentially deadly from patients who might benefit. Mark Flatten of the Goldwater Institute comments.